The protein encoded by this fusion gene is the constitutively active tyrosine kinase BCR-ABL, which drives the malignant process in CML cells and represents the primary target of therapy [1]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.